-+ 0.00%
-+ 0.00%
-+ 0.00%

RPT-ORIC® PHARMACEUTICALS ANNOUNCES INITIATION OF HIMALAYAS-1 PHASE 3 TRIAL IN MCRPC EVALUATING RINZIMETOSTAT IN COMBINATION WITH NUBEQA® (DAROLUTAMIDE), SUPPORTED BY CLINICAL COLLABORATION WITH BAYER

Reuters·07/14/2026 20:20:48

Please log in to view news